21-Gene Recurrence Assay Associated With Favorable Metabolic Profiles in HR-Positive, HER2-Negative Early-Stage Breast Cancer Patients

Yifei Zhu, Tiange Wang, Yiwei Tong, Xiaosong Chen, Kunwei ShenFrontiers in Endocrinology 2021 · DOI

TL;DR

This study investigates the relationship between a 21-gene recurrence assay (RS) and metabolic profiles in early-stage breast cancer patients. It reveals that a lower 21-gene RS is associated with more favorable metabolic markers, and importantly, the prognostic power of the 21-gene RS is amplified in patients with healthier metabolic profiles.

What Problem Does This Paper Address?

Breast cancer recurrence is a major concern, and predicting it accurately is crucial for tailoring treatment. The 21-gene recurrence assay (RS) is a well-established tool for assessing the risk of distant recurrence in HR-positive, HER2-negative early-stage breast cancer, guiding decisions on adjuvant chemotherapy. However, the influence of a patient's overall metabolic health on the accuracy and prognostic impact of this genetic test has not been thoroughly explored, particularly in diverse populations like Chinese women. This paper aims to bridge this gap by examining how metabolic factors (like obesity, insulin resistance, and dyslipidemia) interact with the 21-gene RS in predicting breast cancer recurrence.

Methods

The researchers conducted a prospective study involving 1,038 Chinese women diagnosed with HR-positive, HER2-negative early-stage breast cancer. They collected comprehensive clinical data, including demographic information, tumor characteristics, and importantly, a range of metabolic factors and biomarkers related to insulin and the insulin-like growth factor (IGF) axis.

Key metabolic factors measured included:

  • Body Mass Index (BMI): Calculated from weight and height.
  • Homeostasis Model Assessment of Insulin Resistance (HOMA-IR): A measure of insulin resistance derived from fasting insulin and glucose levels.
  • Fasting Glucose, Blood Pressure (SBP/DBP), Total Cholesterol, HDL, LDL, and Triglycerides: Standard clinical measurements.

Biomarkers of the insulin and IGF axis included:

  • Insulin and C-peptide: Indicators of insulin production and secretion.
  • IGF1 and IGFBP3: Hormones involved in cell growth and metabolism.
  • IGF1/IGFBP3 ratio: A marker of IGF-1 bioavailability.

The 21-gene recurrence assay (RS) was performed on tumor tissue. Statistical analyses involved general linear models to assess associations between the 21-gene RS and metabolic factors, and Cox proportional hazards models to evaluate the risk of breast cancer recurrence, with adjustments for various clinical confounders. Crucially, they also examined interaction terms to see if metabolic profiles modified the prognostic impact of the 21-gene RS.

Datasets

The study utilized data from the Shanghai Jiao Tong University Breast Cancer Database, which prospectively collected information from 1,038 patients between 2012 and 2017. This dataset is specific to Chinese women with HR-positive, HER2-negative early-stage breast cancer and includes detailed clinical, genomic, and metabolic measurements. No new benchmark datasets were introduced.

Key Insights and Ideas

  • Metabolic Health and Genetic Risk are Linked: The study provides strong evidence that a lower 21-gene recurrence score (indicating lower risk of recurrence) is significantly associated with a healthier metabolic profile. This suggests that the biological pathways influencing cancer recurrence are intertwined with metabolic regulation.
  • The "Favorable" Profile is Key: The prognostic impact of the 21-gene RS is not uniform across all patients. It appears to be more pronounced in women who already have favorable metabolic profiles (e.g., not obese, no insulin resistance, normal blood sugar, etc.). This implies that the genetic predisposition to recurrence, as measured by the RS, might be amplified or more readily expressed in a metabolically healthy environment.
  • Gene Expression Reflects Metabolic Status: The study delves into the associations between individual cancer-related genes (measured by their ACt values) and metabolic factors. This offers a more granular understanding of how specific genes within the 21-gene panel might be influenced by or influence metabolic pathways. For instance, certain genes showed inverse associations with BMI and HOMA-IR, and positive associations with HDL.
  • Potential for Personalized Prognosis: By highlighting the interaction between metabolic status and the 21-gene RS, the findings suggest that a more precise prognostic prediction could be achieved by integrating both genetic and metabolic information. This could lead to more personalized treatment strategies.

Key Results

  • The 21-gene RS was inversely associated with Body Mass Index (BMI), HOMA-IR, insulin, and C-peptide, and positively associated with high-density lipoprotein cholesterol (HDL).
  • Each 10-unit increase in the 21-gene RS was associated with a 28% higher risk of breast cancer recurrence in the overall cohort.
  • This association was more pronounced in patients with favorable metabolic profiles:
  • Without obesity: 34% higher risk per 10-unit RS increase.
  • Without insulin resistance: 31% higher risk per 10-unit RS increase.
  • Without hyperglycemia: 44% higher risk per 10-unit RS increase.
  • Without hypertension: 28% higher risk per 10-unit RS increase.
  • Without dyslipidemia: 29% higher risk per 10-unit RS increase.
  • The prognostic impact was even stronger in patients with low levels of insulin, C-peptide, or a low IGF1/IGFBP3 ratio (41-155% higher risk per 10-unit RS increase).
  • While interactions were not statistically significant in all cases, the trend clearly indicated that the 21-gene RS's predictive power was amplified in metabolically healthier individuals.

Limitations and Future Work

The authors acknowledge several limitations:

  • Limited Power for Interaction Detection: The relatively short follow-up period and the number of recurrence events may have limited the statistical power to detect significant interactions between the 21-gene RS and metabolic stratifications.
  • Potential for Confounding: Despite adjusting for many confounders, residual or unmeasured confounding, as well as reverse causality, cannot be entirely ruled out.
  • Single Time Point Measurements: Blood samples and clinical measurements were collected only before surgery. This might not fully capture dynamic changes that could occur during or after treatment.

Future work could focus on:

  • Longer Follow-up Studies: To increase statistical power for detecting interactions.
  • Investigating Causal Mechanisms: Further research into the biological pathways linking metabolic health, gene expression, and cancer recurrence.
  • Prospective Validation: Confirming these findings in larger, independent cohorts.
  • Integrating Metabolic Data into Risk Prediction Models: Exploring how to best combine genetic and metabolic information for more accurate prognostic assessments and treatment guidance.

Summary updated

Abstract

The 21-gene RS was related to favorable metabolic profiles including lower BMI, HOMA-IR, insulin, and C-peptide, and higher HDL in Chinese breast cancer patients, and its prognostic impact on breast cancer recurrence was more likely to present among patients with relatively favorable metabolic profiles.
BibTeX
@inproceedings{zhu2021gene,
  author = {Yifei Zhu and Tiange Wang and Yiwei Tong and Xiaosong Chen and Kunwei Shen},
  title = {{21-Gene Recurrence Assay Associated With Favorable Metabolic Profiles in HR-Positive, HER2-Negative Early-Stage Breast Cancer Patients}},
  booktitle = {Frontiers in Endocrinology},
  year = {2021},
  doi = {10.3389/fendo.2021.725161},
}
Figure